ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 676

Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease

Gabriele Valentini1, Antonella Marcoccia2, Michele Iudici3, Serena Vettori1 and Giovanna Cuomo3, 1Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, 2Angiology Unit, Sandro Pertini Hospital, Rome, Italy, 3Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: To investigate  whether patients affected with any of the 3 subsets of  early systemic sclerosis (SSc)  i.e. Raynaud’s Phenomenon (RP) with  SSc marker autoantibody (ACA or anti-Scl70 or anti-RNA polymerase III or anti-fibrillarin or anti-Th/To) and  typical capillaroscopic findings (megacapillaries and/or avascular areas) (subset I); or autoantibody positive only (subset II); or capillaroscopy positive only (subset III) (1) and unsatisfying the 2012 ACR/EULAR classification criteria for SSc (2) at admission  differ in the lag time to satisfy the new SSc classification  criteria.

Methods: Early SSc patients consecutively admitted to a Rheumatology  and an Angiology center and unsatisfying the 2012 ACR/EULAR classification criteria for SSc at admission, were subdivided into the 3 above referred subsets and followed-up for 7-101 months (median 45). They were re-evaluated six-monthly by history, clinical examination, B-mode echoDopplercardiography and Lung functional study including DLCO evaluation and yearly by lung HRCT to assess whether and when each of them satisfied new ACR/EULAR classification criteria i.e. developed a disease score ≥9 (2).               

Results: During the follow-up, 11 out of 21 subset I patients (52.3%) (baseline score  8); 10 out of 15 subset II patients (66.6%) (baseline score 6) and 0 out of 24 subset III patients (baseline score 5-7)  satisfied the criteria; the difference being significant  between each of the 2 autoantibody positive (subsets I and II) and the capillaroscopic positive-autoantibody negative subset  (subset I versus III: X2  by  log rank test=17.45, p=0.0001; subset II versus III: X2 =11.04, p=0.0009), no difference being detected between the 2 autoantibody positive subsets (X2 =0.55, p=0.454). The 11 subset I patients satisfied the criteria  because of the development of teleangectasias in 5 cases; puffy fingers in 3 cases; lung fibrosis in 2 cases; digital ulcers in 1 case. The 10 subset II patients did it because of the development of at least 2 of the following manifestations: scleroderma capillaroscopic pattern in 5 cases, teleangectasias in 5 cases, puffy fingers in 5 cases, digital ulcers in 3 cases, pulmonary hypertension in 1 case and lung fibrosis in 1 case. Despite the unfulfillment of the criteria, among the 24 subset III patients, 21 of whom already presented puffy fingers at baseline, 2 developed telangectasias, 1 digital ulcers, 4 a DLCO<80%.

Conclusion:

We have recently pointed out that autoantibody positive early SSc patients differ from subset III patients in the pattern of activation markers (increased serum concentration of procollagen I carbossipropeptide versus increased serum concentration of E-selectin) and preclinical internal organ involvement  (higher prevalence of  decreased DLCO) (3). Here we point out that autoantibody positive patients present a faster pace of the disease.                                                             

 

 

 

References

 

1) Koenig M et al. Arthritis Rheum. 2008;58:3902-12

2) Van den Hoogen F et al. Eular Congress 2013, OP0033

3) Valentini G et al. Arthritis Res Ther. 2013; 29;15:R63


Disclosure:

G. Valentini,
None;

A. Marcoccia,
None;

M. Iudici,
None;

S. Vettori,
None;

G. Cuomo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-systemic-sclerosis-marker-autoantibody-positive-patients-have-a-faster-pace-of-the-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology